Stockreport

Adagene Announces Licensing Agreement with Third Arc Bio for Development of Two Masked CD3 T Cell Engagers Utilizing SAFEbody® Technology [Yahoo! Finance]

Adagene Inc. - ADS, each representing 1.25 ordinary shares  (ADAG) 
PDF Third Arc Bio, Inc. (“Third Arc Bio”), today announced a licensing agreement under which Third Arc Bio will utilize Adagene's SAFEbody technology platform to generate ma [Read more]